Education
About Us
Working with TipRanks
Follow Us
Aura Biosciences Inc (AURA)
NASDAQ:AURA
AURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.77 - $12.38
Previous CloseN/A
Volume82.15K
Average Volume (3M)208.19K
Market Cap
$298.34M
Enterprise Value$277.67M
Total Cash (Recent Filing)$41.08M
Total Debt (Recent Filing)$19.56M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
May 08, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding50,225,310
10 Day Avg. Volume304,030
30 Day Avg. Volume208,186
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-214.42
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$22.50Price Target Upside278.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Aura Biosciences Inc News
See All AURA News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsClinical data presented at EAU demonstrated several complete responses in NMIBC patients, indicating effective treatment outcomes.
Financial StabilityThe company reported $151 million in cash and cash equivalents, expected to provide financial runway into the second half of 2026.
Medical AdvancementsThe dual mechanism of action of bel-sar, which includes direct tumor cell necrosis and an immune response, is validated with potential applications beyond bladder cancer.
Bears Say
CompetitionThe neoadjuvant space is more competitive, with a number of programs in the post BCG/high risk setting.
Treatment LimitationsThere are currently no drugs approved for the primary treatment of low-grade NMIBC, despite the large market opportunity and a high unmet need.
---
Ownership Overview
3.90% Insiders
16.97% Mutual Funds
52.17% Other Institutional Investors
18.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $5.77 and its highest was $12.38 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $298.34M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is May 08, 2025 which is in 39 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Mar 24, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.444 by -$0.076.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.48.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 50,225,310 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.444. Following the earnings report the stock price went up 1.143%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
---
Aura Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (278.79% Upside)
$22.50 (278.79% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $334.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.23%
12-Months-Change
Fundamentals
Return on Equity
-46.01%
Trailing 12-Months
Asset Growth
-28.45%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
---
AURA Stock 12 Month Forecast
Average Price Target
$22.50
▲(278.79% Upside)
Technical Analysis
Sarepta Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering AURA
1 Year
1 Year Success Rate
4/19 ratings generated profit
1 Year Average Return
-18.73%
reiterated a buy rating 4 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 21.05% of your transactions generating a profit, with an average return of -18.73% per trade.
---